Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α(2)-adrenoceptors and 5-HT(1) receptors

BACKGROUND: Dihydroergotamine (DHE) is an antimigraine drug that produces cranial vasoconstriction and inhibits trigeminal CGRP release; furthermore, it inhibits the vasodepressor sensory CGRPergic outflow, but the receptors involved remain unknown. Prejunctional activation of α(2A/2C)-adrenergic, s...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Hernández, Abimael, Lozano-Cuenca, Jair, Marichal-Cancino, Bruno A., MaassenVanDenBrink, Antoinette, Villalón, Carlos M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970131/
https://www.ncbi.nlm.nih.gov/pubmed/29802544
http://dx.doi.org/10.1186/s10194-018-0869-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970131/
https://www.ncbi.nlm.nih.gov/pubmed/29802544
http://dx.doi.org/10.1186/s10194-018-0869-8

Ejemplares similares